SPTA1
Basic information
Region (hg38): 1:158610704-158686715
Links
Phenotypes
GenCC
Source:
- elliptocytosis 2 (Strong), mode of inheritance: AD
- hereditary spherocytosis type 3 (Definitive), mode of inheritance: AR
- elliptocytosis 2 (Strong), mode of inheritance: AD
- hereditary spherocytosis (Supportive), mode of inheritance: AD
- hereditary elliptocytosis (Supportive), mode of inheritance: AD
- pyropoikilocytosis, hereditary (Strong), mode of inheritance: AR
- hereditary spherocytosis type 3 (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Spherocytosis, type 3; Pyropoikilocytosis , hereditary; Ellipsocytosis 2 | AD/AR | Hematologic | Individuals have been described with severe hemolytic anemia, which has been treated by interventions such as frequent transfusions and splenectomy | Hematologic | 1191563; 7070419; 2987946; 3785322; 3597773; 2567189; 2794061; 1541680; 8226774; 8941647; 16150946; 21251457 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (45 variants)
- Hereditary spherocytosis type 3 (8 variants)
- Elliptocytosis 2 (6 variants)
- Pyropoikilocytosis, hereditary (4 variants)
- SPTA1-related disorder (3 variants)
- Hereditary spherocytosis (2 variants)
- Hemolytic anemia (1 variants)
- Familial hemolytic anemia (1 variants)
- Pyropoikilocytosis, hereditary;Hereditary spherocytosis type 3;Elliptocytosis 2 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SPTA1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 27 | 38 | 21 | 87 | ||
missense | 386 | 26 | 15 | 438 | ||
nonsense | 31 | 31 | 64 | |||
start loss | 1 | |||||
frameshift | 13 | 23 | 36 | |||
inframe indel | 9 | |||||
splice donor/acceptor (+/-2bp) | 24 | 29 | ||||
splice region | 2 | 29 | 12 | 2 | 45 | |
non coding | 47 | 35 | 67 | 151 | ||
Total | 53 | 90 | 470 | 99 | 103 |
Highest pathogenic variant AF is 0.00454
Variants in SPTA1
This is a list of pathogenic ClinVar variants found in the SPTA1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-158610755-C-A | Elliptocytosis 2 • Hereditary spherocytosis type 3 • Pyropoikilocytosis, hereditary | Uncertain significance (Jan 12, 2018) | ||
1-158610763-TA-T | Elliptocytosis • Pyropoikilocytosis, hereditary • Spherocytosis, Recessive | Likely benign (Jun 14, 2016) | ||
1-158610844-A-T | Elliptocytosis 2 • Hereditary spherocytosis type 3 • Pyropoikilocytosis, hereditary | Uncertain significance (Jan 13, 2018) | ||
1-158610877-A-G | Pyropoikilocytosis, hereditary • Elliptocytosis 2 • Hereditary spherocytosis type 3 | Conflicting classifications of pathogenicity (Jan 12, 2018) | ||
1-158610885-C-T | Pyropoikilocytosis, hereditary • Hereditary spherocytosis type 3 • Elliptocytosis 2 | Uncertain significance (Jan 13, 2018) | ||
1-158610923-A-C | Pyropoikilocytosis, hereditary • Elliptocytosis 2 • Hereditary spherocytosis type 3 | Uncertain significance (Jan 13, 2018) | ||
1-158610941-A-G | Hereditary spherocytosis type 3 • Pyropoikilocytosis, hereditary • Elliptocytosis 2 | Uncertain significance (Jan 13, 2018) | ||
1-158610945-G-A | Pyropoikilocytosis, hereditary • Hereditary spherocytosis type 3 • Elliptocytosis 2 | Uncertain significance (Jan 12, 2018) | ||
1-158610968-C-A | Hereditary spherocytosis type 3 • Pyropoikilocytosis, hereditary • Elliptocytosis 2 | Uncertain significance (Jan 12, 2018) | ||
1-158610969-G-A | Hereditary spherocytosis type 3 • Elliptocytosis 2 • Pyropoikilocytosis, hereditary | Benign (Nov 12, 2018) | ||
1-158610970-T-C | Elliptocytosis 2 • Pyropoikilocytosis, hereditary • Hereditary spherocytosis type 3 | Uncertain significance (Jan 13, 2018) | ||
1-158610988-A-G | Elliptocytosis 2 • Hereditary spherocytosis type 3 • Pyropoikilocytosis, hereditary | Benign (Nov 12, 2018) | ||
1-158611097-T-C | Pyropoikilocytosis, hereditary • Elliptocytosis 2 • Hereditary spherocytosis type 3 | Benign (Nov 12, 2018) | ||
1-158611130-A-C | Hereditary spherocytosis type 3 • Pyropoikilocytosis, hereditary • Elliptocytosis 2 | Uncertain significance (Jan 12, 2018) | ||
1-158611131-G-A | Elliptocytosis 2 • Pyropoikilocytosis, hereditary • Hereditary spherocytosis type 3 | Uncertain significance (Jan 13, 2018) | ||
1-158611131-GCA-G | Pyropoikilocytosis, hereditary • Spherocytosis, Recessive • Elliptocytosis | Uncertain significance (Jun 14, 2016) | ||
1-158611131-GCACA-G | Pyropoikilocytosis, hereditary • Elliptocytosis • Spherocytosis, Recessive | Uncertain significance (Jun 14, 2016) | ||
1-158611131-GCACACA-G | Spherocytosis, Recessive • Pyropoikilocytosis, hereditary • Elliptocytosis | Uncertain significance (Jun 14, 2016) | ||
1-158611131-G-GCA | Spherocytosis, Recessive • Pyropoikilocytosis, hereditary • Elliptocytosis | Uncertain significance (Jun 14, 2016) | ||
1-158611131-G-GCACACA | Elliptocytosis • Pyropoikilocytosis, hereditary • Spherocytosis, Recessive | Uncertain significance (Jun 14, 2016) | ||
1-158611131-G-GCACACACA | Elliptocytosis • Spherocytosis, Recessive • Pyropoikilocytosis, hereditary | Uncertain significance (Jun 14, 2016) | ||
1-158611131-G-GCACACACACACA | Pyropoikilocytosis, hereditary • Elliptocytosis • Spherocytosis, Recessive | Uncertain significance (Jun 14, 2016) | ||
1-158611166-C-CACACAT | Elliptocytosis • Pyropoikilocytosis, hereditary • Spherocytosis, Recessive | Uncertain significance (Jun 14, 2016) | ||
1-158611196-G-C | Pyropoikilocytosis, hereditary • Elliptocytosis 2 • Hereditary spherocytosis type 3 | Conflicting classifications of pathogenicity (Jan 13, 2018) | ||
1-158611225-C-T | Hereditary spherocytosis type 3 • Elliptocytosis 2 • Pyropoikilocytosis, hereditary | Uncertain significance (Jan 12, 2018) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SPTA1 | protein_coding | protein_coding | ENST00000368147 | 52 | 75993 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.60e-18 | 1.00 | 124691 | 0 | 109 | 124800 | 0.000437 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -2.25 | 1456 | 1.23e+3 | 1.18 | 0.0000709 | 16002 |
Missense in Polyphen | 569 | 482.03 | 1.1804 | 6693 | ||
Synonymous | -2.89 | 540 | 461 | 1.17 | 0.0000242 | 4375 |
Loss of Function | 6.75 | 57 | 145 | 0.394 | 0.00000844 | 1685 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00103 | 0.00103 |
Ashkenazi Jewish | 0.000596 | 0.000596 |
East Asian | 0.000223 | 0.000222 |
Finnish | 0.000186 | 0.000186 |
European (Non-Finnish) | 0.000434 | 0.000433 |
Middle Eastern | 0.000223 | 0.000222 |
South Asian | 0.000523 | 0.000523 |
Other | 0.000331 | 0.000330 |
dbNSFP
Source:
- Function
- FUNCTION: Spectrin is the major constituent of the cytoskeletal network underlying the erythrocyte plasma membrane. It associates with band 4.1 and actin to form the cytoskeletal superstructure of the erythrocyte plasma membrane.;
- Disease
- DISEASE: Elliptocytosis 2 (EL2) [MIM:130600]: A Rhesus-unlinked form of hereditary elliptocytosis, a genetically heterogeneous, autosomal dominant hematologic disorder. It is characterized by variable hemolytic anemia and elliptical or oval red cell shape. {ECO:0000269|PubMed:1541680, ECO:0000269|PubMed:1638030, ECO:0000269|PubMed:1679439, ECO:0000269|PubMed:1878597, ECO:0000269|PubMed:2384601, ECO:0000269|PubMed:2568861, ECO:0000269|PubMed:2568862, ECO:0000269|PubMed:2794061, ECO:0000269|PubMed:7772539, ECO:0000269|PubMed:8018926, ECO:0000269|PubMed:8193371, ECO:0000269|PubMed:8364215}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hereditary pyropoikilocytosis (HPP) [MIM:266140]: Autosomal recessive hematologic disorder characterized by hemolytic anemia, microspherocytosis, poikilocytosis, and an unusual thermal sensitivity of red cells. {ECO:0000269|PubMed:1878597}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Spherocytosis 3 (SPH3) [MIM:270970]: Spherocytosis is a hematologic disorder leading to chronic hemolytic anemia and characterized by numerous abnormally shaped erythrocytes which are generally spheroidal. SPH3 is characterized by severe hemolytic anemia. Inheritance is autosomal recessive. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Apoptosis - Homo sapiens (human);Developmental Biology;Signal Transduction;Vesicle-mediated transport;Membrane Trafficking;Post-translational protein modification;Metabolism of proteins;Transport to the Golgi and subsequent modification;Asparagine N-linked glycosylation;Interaction between L1 and Ankyrins;RAF/MAP kinase cascade;MAPK1/MAPK3 signaling;MAPK family signaling cascades;NCAM signaling for neurite out-growth;L1CAM interactions;COPI-mediated anterograde transport;Axon guidance;ER to Golgi Anterograde Transport
(Consensus)
Recessive Scores
- pRec
- 0.0869
Intolerance Scores
- loftool
- 0.806
- rvis_EVS
- 4.85
- rvis_percentile_EVS
- 99.79
Haploinsufficiency Scores
- pHI
- 0.206
- hipred
- N
- hipred_score
- 0.328
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.579
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | High | High | High |
Primary Immunodeficiency | High | High | High |
Cancer | High | High | High |
Mouse Genome Informatics
- Gene name
- Spta1
- Phenotype
- homeostasis/metabolism phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); liver/biliary system phenotype; respiratory system phenotype; immune system phenotype; renal/urinary system phenotype; skeleton phenotype; digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); reproductive system phenotype; pigmentation phenotype;
Gene ontology
- Biological process
- MAPK cascade;lymphocyte homeostasis;porphyrin-containing compound biosynthetic process;endoplasmic reticulum to Golgi vesicle-mediated transport;plasma membrane organization;actin filament organization;axon guidance;regulation of cell shape;hemopoiesis;positive regulation of protein binding;positive regulation of T cell proliferation;actin filament capping
- Cellular component
- cytosol;spectrin;spectrin-associated cytoskeleton;actin cytoskeleton;axon;intrinsic component of the cytoplasmic side of the plasma membrane;cuticular plate
- Molecular function
- Ras guanyl-nucleotide exchange factor activity;structural constituent of cytoskeleton;calcium ion binding;protein binding;protein heterodimerization activity;actin filament binding